The Path to Progress: Preparing the Healthcare Ecosystem for Celiac Disease Therapeutics

Byline: Health Policy Desk

On June 12, 2026, a pivotal moment in the history of autoimmune research occurred. The Celiac Disease Foundation (CDF), in collaboration with the Society for the Study of Celiac Disease, hosted the "2026 National Celiac Disease Policy Symposium: From Diagnosis to Coverage."

For years, the celiac community has operated under a single, rigorous standard of care: the gluten-free diet. While essential, this "treatment" is a lifestyle burden that often fails to address the persistent inflammation and systemic damage experienced by many patients. As several promising therapeutics move through the clinical trial pipeline, the symposium served as a critical summit to ensure that when these drugs reach FDA approval, the path to patient access is not blocked by bureaucratic, diagnostic, or insurance-related hurdles.

The Mandate: Aligning Policy with Innovation

The core mission of the symposium was "alignment." For a new drug to successfully reach the pharmacy shelf, it requires a synchronized effort between diagnostic experts, pharmaceutical developers, regulatory bodies, and the often-opaque world of health insurance payers.

The virtual gathering brought together the brightest minds in gastroenterology, clinical research, and health policy. The objective was to create a transparent, evidence-based roadmap for how patients will qualify for, and receive insurance coverage for, the next generation of celiac treatments. By fostering a dialogue between those who study the disease and those who control the funding, the symposium sought to prevent a scenario where a life-changing drug is approved but remains inaccessible to the patient population that needs it most.

Chronology: A Roadmap for the Future of Care

The symposium was structured as a chronological deep dive into the patient journey—from the moment of initial diagnostic testing to the final approval of insurance coverage.

Panel 1: Diagnostic Alignment in a Therapeutic Era

Led by Dr. Christopher Cao, Dr. Marie Robert, Dr. Vahe Badalyan, Dr. Jack Doyle, and Dr. Jennifer Sealy-Voyksner, this session addressed the "gold standard" of diagnosis. As we move into an era of targeted therapeutics, the precision of our diagnostic records becomes paramount.

Patient Action Item: The experts emphasized that patients must take ownership of their medical history. If you were diagnosed years ago, you must track down your original biopsy reports and serology results. Without a formalized diagnostic record, proving eligibility for future treatments may be impossible.

Panel 2: Trial Design, Genotype, and Regulatory Signals

The focus shifted to the scientific rigor required by the FDA. Dr. Edwin Liu, Dr. Amelie Therrien, and their colleagues explored how genetic markers, particularly HLA-DQ2 and HLA-DQ8, influence trial eligibility.

Patient Action Item: Knowledge is power. Patients are urged to obtain their full HLA genetic testing results, detailing the specific alleles present. This information is no longer just a curiosity; it will likely be a prerequisite for clinical trial participation and potential therapeutic eligibility.

Panel 3: Defining "Treatment-Eligible" Celiac Disease

What defines a patient who needs a drug? Dr. Ben Lebwohl, Dr. Anne Lee, and their panel explored the nuance of lived experience. Is a diagnosis alone enough, or must there be refractory symptoms?

Patient Action Item: Documenting the "invisible" burden is critical. Patients should keep records of ongoing symptoms, nutritional deficiencies, and the quality-of-life impacts of the gluten-free diet. Routine evaluations with a registered dietitian—at least twice yearly—are essential to maintaining a record of medical necessity.

Panel 4: Payer Coverage Strategy

Perhaps the most crucial session for long-term access, this panel featured industry experts like Jonathan Blum and Dr. Alexander Oshmyansky. The discussion centered on what evidence insurance companies require to approve coverage.

Patient Action Item: Patients employed by self-insured organizations should engage with their HR departments. Self-insured employers often have the authority to influence their pharmacy benefit managers, making them key stakeholders in the conversation about drug coverage.

Panel 5: Advocacy Roadmaps

Drawing lessons from other chronic conditions like Crohn’s or Type 1 Diabetes, the final panel, featuring Aaron Turner-Phifer and Michelle Rice, provided a blueprint for patient advocacy. The lesson was clear: policymakers and payers respond to organized, data-driven patient advocacy.

Supporting Data and the "Therapeutic Era"

The symposium underscored that we are at an inflection point. With multiple therapeutics currently in Phase 2 and Phase 3 trials, the question is no longer "if" a drug will be developed, but "how" it will be integrated into the existing healthcare system.

The data presented by experts suggest that the definition of "treatment success" is shifting. While historical success was measured strictly by intestinal healing, future metrics will likely include:

• Symptom mitigation: Quantitative improvements in patient-reported outcomes.
• Nutritional stability: Reversal of deficiencies despite dietary adherence.
• Quality of Life (QoL): Validated assessments of the psychosocial impact of the disease.

The consensus among the speakers was that the healthcare system is currently ill-equipped to handle the nuance of celiac disease. Unlike conditions with clear physiological markers for drug efficacy, celiac disease involves complex interactions between the gut microbiome, genetic predisposition, and environmental triggers. The symposium participants argued that for insurance companies to cover these drugs, they need a standardized, reproducible set of "treatment-eligible" criteria.

Official Responses and Strategic Implications

The Celiac Disease Foundation (CDF) has assumed a leading role as a liaison between these disparate groups. By convening regulators and insurers, the Foundation is aiming to preempt the "denial loop"—a common frustration in rare and autoimmune diseases where insurers deny coverage based on a lack of standardized clinical definitions.

"We are building the bridge while we are walking on it," one participant noted during the closing plenary. The implication for the celiac community is significant. We are moving from a passive patient model—where the patient waits for the diet to work—to an active patient model, where individuals must curate their health data to prove their need for advanced medical intervention.

The Road Ahead: Why This Matters

The 2026 Symposium was more than a academic conference; it was a call to action. For the estimated millions living with celiac disease, the potential for non-dietary treatments represents a return to a sense of normalcy that has been missing for decades.

However, the symposium highlighted a sobering reality: medical innovation does not automatically equate to patient access. Without the groundwork laid by this symposium, even a highly effective drug could be sidelined by high copays, restrictive "step therapy" requirements, or narrow diagnostic definitions used by insurance companies to limit coverage.

Summary of Essential Patient Actions:

1. Consolidate Records: Gather your original biopsy and blood test results. Store them in a secure, digital format.
2. Know Your HLA: If you have undergone HLA testing, request the detailed report including specific allele variants.
3. Document the Burden: Keep a log of persistent symptoms and nutritional hurdles. Ensure these are documented in your electronic health record by your gastroenterologist.
4. Engage with Experts: Maintain a relationship with a dietitian specializing in celiac disease to track your progress and nutritional status formally.
5. Advocate: Stay informed about the Celiac Disease Foundation’s policy alerts. Your voice, backed by your data, is the most powerful tool for changing insurance coverage policies.

Conclusion

The 2026 National Celiac Disease Policy Symposium provided a clear signal to the pharmaceutical and insurance industries: the celiac community is organized, informed, and ready for the next era of treatment. By aligning diagnostic standards with regulatory requirements and payer expectations, the stakeholders involved are working to ensure that when the next breakthrough occurs, no patient is left behind.

The Celiac Disease Foundation continues to act as a catalyst, ensuring that the patient perspective remains central to these high-level discussions. With the support of sponsors such as Takeda Pharmaceuticals, Forte Biosciences, and others, the path toward a future where celiac disease is managed with more than just a diet is becoming increasingly clear.

For those interested in reviewing the specific arguments presented by the experts, the full recordings of the symposium are available on the Celiac Disease Foundation website. The work has only just begun, but the foundation for success has been firmly established.